The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study
Open accessAbstract
BACKGROUND: Analysis of circulating tumour DNA could stratify cancer risk in symptomatic patients. We aimed to evaluate the performance of a methylation-based multicancer early detection (MCED) diagnostic test in symptomatic patients referred from primary care. METHODS: We did a multicentre, prospective, observational study at National Health Service (NHS) hospital sites in England and Wales. Participants aged 18 or older referred with non-specific symptoms or symptoms potentially due to gynaecological, lung, or upper or lower gastrointestinal cancers were included and gave a blood sample when they attended for urgent investigation. Participants were excluded if they had a history of or had received treatment for an invasive or haematological malignancy diagnosed within the preceding 3 years, were taking cytotoxic or demethylating agents that might interfere with the test, or had participated in another study of a GRAIL MCED test. Patients were followed until diagnostic resolution or up to 9 months. Cell-free DNA was isolated and the MCED test performed blinded to the clinical outcome. MCED predictions were compared with the diagnosis obtained by standard care to establish the primary outcomes of overall positive and negative predictive value, sensitivity, and specificity. Outcomes were assessed in participants with a valid MCED test result and diagnostic resolution. SYMPLIFY is registered with ISRCTN (ISRCTN10226380) and has completed follow-up at all sites. FINDINGS: 6238 participants were recruited between July 7 and Nov 30, 2021, across 44 hospital sites. 387 were excluded due to staff being unable to draw blood, sample errors, participant withdrawal, or identification of ineligibility after enrolment. Of 5851 clinically evaluable participants, 376 had no MCED test result and 14 had no information as to final diagnosis, resulting in 5461 included in the final cohort for analysis with an evaluable MCED test result and diagnostic outcome (368 [6·7%] with a cancer diagnosis and 5093 [93·3%] without a cancer diagnosis). The median age of participants was 61·9 years (IQR 53·4-73·0), 3609 (66·1%) were female and 1852 (33·9%) were male. The MCED test detected a cancer signal in 323 cases, in whom 244 cancer was diagnosed, yielding a positive predictive value of 75·5% (95% CI 70·5-80·1), negative predictive value of 97·6% (97·1-98·0), sensitivity of 66·3% (61·2-71·1), and specificity of 98·4% (98·1-98·8). Sensitivity increased with increasing age and cancer stage, from 24·2% (95% CI 16·0-34·1) in stage I to 95·3% (88·5-98·7) in stage IV. For cases in which a cancer signal was detected among patients with cancer, the MCED test's prediction of the site of origin was accurate in 85·2% (95% CI 79·8-89·3) of cases. Sensitivity 80·4% (95% CI 66·1-90·6) and negative predictive value 99·1% (98·2-99·6) were highest for patients with symptoms mandating investigation for upper gastrointestinal cancer. INTERPRETATION: This first large-scale prospective evaluation of an MCED diagnostic test in a symptomatic population demonstrates the feasibility of using an MCED test to assist clinicians with decisions regarding urgency and route of referral from primary care. Our data provide the basis for a prospective, interventional study in patients presenting to primary care with non-specific signs and symptoms. FUNDING: GRAIL Bio UK.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crosby, D., Bhatia, S., Brindle, K. M., Coussens, L. M., Dive, C., Emberton, M., Esener, S., Fitzgerald, R. C., Gambhir, S. S., Kuhn, P., et al. (2022) · Science · doi:10.1126/science.aay9040 · Cited by 1,379
Smith, C. F., Drew, S., Ziebland, S., & Nicholson, B. D. (2020) · British Journal of General Practice · doi:10.3399/bjgp20x712301 · Cited by 87
Self-citation
Cited by
Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study
Schrag, D., Beer, T. M., McDonnell, C. H., Nadauld, L., Dilaveri, C. A., Reid, R., Marinac, C. R., Chung, K. C., Lopatin, M., Fung, E. T., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01700-2 · Cited by 396
Derraz, B., Breda, G., Kaempf, C., Baenke, F., Cotte, F., Reiche, K., Köhl, U., Kather, J. N., Eskenazy, D., & Gilbert, S. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00517-w · Cited by 94
Metadata
- Authors
- Nicholson, B. D., Oke, J., Virdee, P. S., Harris, D. A., O'Doherty, C., Park, J. E., Hamady, Z., Sehgal, V., Millar, A., Medley, L., Tonner, S., Vargova, M., Engonidou, L., Riahi, K., Luan, Y., Hiom, S., Kumar, H., Nandani, H., Kurtzman, K. N., Yu, L.-M., Freestone, C., Pearson, S., Hobbs, F. R., Perera, R., & Middleton, M. R.
- Venue
- The Lancet Oncology
- Publisher
- Elsevier BV
- Published
- 2023-07
- Volume
- 24
- Issue
- 7
- Pages
- 733-743
- ISSN
- 1470-2045 (ISSN-L)
- OpenAlex
- W4381435277
- Cited by
- 188
- References
- 2
- FWCI
- 18.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study. https://app.cochat.ai/papers/10.1016/s1470-2045(23)00277-2
- The paper
- Nicholson, B. D., Oke, J., Virdee, P. S., Harris, D. A., O'Doherty, C., Park, J. E., Hamady, Z., Sehgal, V., Millar, A., Medley, L., Tonner, S., Vargova, M., Engonidou, L., Riahi, K., Luan, Y., Hiom, S., Kumar, H., Nandani, H., Kurtzman, K. N., . . . Middleton, M. R. (2023). Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(23)00277-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.